• NeurogesX Inc., of San Mateo, Calif., said the FDA's Anesthetic and Analgesic Drug Products Advisory Committee did not recommend approval of Qutenza (capsaicin 8 percent patch) for management of neuropathic pain related to HIV-associated peripheral neuropathy.